

Supplemental Table 1. Effects of Covariates on Study Endpoints

| covariate | Outcome* | | | | | |
|------------------------------------|-----------------------|----------------------|----------------------|----------------------|---------------------------|----------------------|
| | Disease-free survival | Distant Metastasis | Local Progression | Biochemical Failure | Disease-specific Survival | Overall Survival |
| Treatment LDAD vs. SDAD | 0.71 (0.64, 0.79) | 0.64 (0.51, 0.80) | 0.54 (0.42, 0.69) | 0.58 (0.50, 0.66) | 0.70 (0.55, 0.89) | 0.88 (0.79, 0.98) |
| T Stage T3 vs. T2 | 1.08 (0.97, 1.21) | 1.62 (1.28, 2.05) | 1.33 (1.04, 1.70) | 1.18 (1.03, 1.36) | 1.51 (1.18, 1.94) | 1.05 (0.93, 1.17) |
| T Stage T4 vs. T2 | 1.47 (1.11, 1.93) | 3.64 (2.35, 5.66) | 1.68 (0.94, 2.99) | 1.66 (1.18, 2.34) | 3.16 (1.96, 5.12) | 1.73 (1.30, 2.31) |
| N stage N0/Nx vs. N1, N2 | 0.59 (0.45, 0.76) | 0.55 (0.37, 0.81) | 0.70 (0.43, 1.15) | 0.56 (0.42, 0.75) | 0.47 (0.31, 0.70) | 0.72 (0.55, 0.95) |
| Initial PSA >30 vs. 0-30 | 1.34 (1.20, 1.50) | 1.39 (1.12, 1.73) | 1.03 (0.80, 1.32) | 1.68 (1.46, 1.94) | 1.33 (1.05, 1.68) | 1.04 (0.92, 1.18) |
| Gleason 8-10 vs. <8 | 1.27 (1.12, 1.44) | 2.10 (1.68, 2.63) | 1.41 (1.08, 1.82) | 1.33 (1.14, 1.56) | 2.20 (1.73, 2.81) | 1.32 (1.15, 1.50) |
| Age (per year) | 1.01 (1.01, 1.02) | 0.97 (0.95, 0.98) | 0.98 (0.96, 1.00) | 0.98 (0.97, 0.99) | 0.98 (0.96, 1.00) | 1.05 (1.04, 1.06) |

*Table entries are hazard ratio with 95% confidence interval for first vs. second category of covariate from model containing all covariates shown